1. Chamberlain MC: Neoplastic meningitis. Current neurology and neuroscience reports 2008, 8(3):249-258.
2. Martins SJ, Azevedo CR, Chinen LT, Cruz MR, Peterlevitz MA, Gimenes DL: Meningeal carcinomatosis in solid tumors. Arquivos de Neuro-Psiquiatria 2011, 69(6):973-980.
3. Murtaza M, Dawson SJ, Tsui DWY, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong ASC: Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497(7447):108-112.
4. Dawson SJ, Tsui DWY, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahleraraujo B: Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer. New England Journal of Medicine 2013, 368(13):1199-1209.
5. Bettegowda C, Sausen M, Leary R, Kinde I, Agrawal N, Bartlett B, Wang H, Luber B, Kinzler K, Vogelstein B: DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES. Science Translational Medicine 2014, 6(224):224ra224.
6. Mattos-Arruda LD, Mayor R, Ng CKY, Weigelt B, Mart´Inez-Ricarte F, Torrejon D, Oliveira M, Arias A, Raventos C, Tang J: Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications 2015, 6:8839.
7. Li M, Dressman D, He Y, Shen D, Szabo S, Goodman SN, Juhl H, Kinzler KW, Vogelstein B: Detection and Quantification of Mutations in the Plasma of Patients with Colorectal Tumors. Proceedings of the National Academy of Sciences of the United States of America 2005, 102(45):16368-16373.
8. Li YS, Jiang BY, Yang JJ, Zhang XC, Zhang Z, Ye JY, Zhong WZ, Tu HY, Chen HJ, Wang Z: Unique Genetic Profiles from Cerebrospinal Fluid Cell-free DNA in Leptomeningeal Metastases of EGFR-mutant Non-Small Cell Lung Cancer: A New Medium of Liquid Biopsy. Annals of Oncology Official Journal of the European Society for Medical Oncology 2018, 29(11).
9. Pentsova EI, Shah RH, Tang J, Boire A, You D, Briggs S, Omuro A, Lin X, Fleisher M, Grommes C et al: Evaluating Cancer of the Central Nervous System Through Next-Generation Sequencing of Cerebrospinal Fluid. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2016, 34(20):2404-2415.
10. Cai X, Sheng J, Tang C, Nandakumar V, Ye H, Ji H, Tang H, Qin Y, Guan H, Lou F: Frequent mutations in EGFR, KRAS and TP53 genes in human lung cancer tumors detected by ion torrent DNA sequencing. Plos One 2014, 9(4):e95228.
11. Xu Z, Huo X, Tang C, Ye H, Nandakumar V, Lou F, Zhang D, Jiang S, Sun H, Dong H: Frequent KIT mutations in human gastrointestinal stromal tumors. Scientific Reports 2014, 4:5907.
12. Bai X, Zhang E, Ye H, Nandakumar V, Wang Z, Chen L, Tang C, Li J, Li H, Zhang W: PIK3CA and TP53 gene mutations in human breast cancer tumors frequently detected by ion torrent DNA sequencing. Plos One 2014, 9(6):e99306.
13. Grasso C, Butler T, Rhodes K, Quist M, Neff TL, Moore S, Tomlins SA, Reinig E, Beadling C, Andersen M et al: Assessing copy number alterations in targeted, amplicon-based next-generation sequencing data. The Journal of molecular diagnostics : JMD 2015, 17(1):53-63.
14. Huang da W, Sherman BT, Lempicki RA: Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nature protocols 2009, 4(1):44-57.
15. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM: Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine 2014, 6(224):224ra224.
16. Fruman DA, Rommel C: PI3K and cancer: lessons, challenges and opportunities. Nature Reviews Drug Discovery 2014, 13(2):140-156.
17. Soler A, Angulourarte A, Graupera M: PI3K at the crossroads of tumor angiogenesis signaling pathways. Molecular & Cellular Oncology 2015, 2(2):-.
18. Z L, Y Z, X Y, Y C, X T, J W, N J, T L, J W, J D: Estrogen stimulates the invasion of ovarian cancer cells via activation of the PI3K/AKT pathway and regulation of its downstream targets E‑cadherin and α‑actinin‑4. Molecular Medicine Reports 2014, 10(5):2433.
19. Ding Z, Liang J, Lu Y, Yu Q, Songyang Z, Lin SY, Mills GB: A retrovirus-based protein complementation assay screen reveals functional AKT1-binding partners. Proceedings of the National Academy of Sciences of the United States of America 2006, 103(41):15014-15019.
20. Koay MH, Crook M, Stewart CJ: Cyclin D1, E-cadherin and beta-catenin expression in FIGO Stage IA cervical squamous carcinoma: diagnostic value and evidence for epithelial-mesenchymal transition. Histopathology 2012, 61(6):1125-1133.
21. Xiong H, Hong J, Du W, Lin Y, Ren L, Wang Y, Su W, Wang J, Cui Y, Wang Z: Roles of STAT3 and ZEB1 Proteins in E-cadherin Down-regulation and Human Colorectal Cancer Epithelial-Mesenchymal Transition. Journal of Biological Chemistry 2012, 287(8):5819-5832.
22. Lau MT, Klausen C, Leung PCK: E-cadherin inhibits tumor cell growth by suppressing PI3K|[sol]|Akt signaling via |[beta]|-catenin-Egr1-mediated PTEN expression. Oncogene 2011, 30(24):2753.
23. Bian C, Liu Z, Li D, Zhen L: PI3K/AKT inhibition induces compensatory activation of the MET/STAT3 pathway in non-small cell lung cancer. Oncology letters 2018, 15(6):9655-9662.
24. Xu S, Li Y, Lu Y, Huang J, Ren J, Zhang S, Yin Z, Huang K, Wu G, Yang K: LZTS2 inhibits PI3K/AKT activation and radioresistance in nasopharyngeal carcinoma by interacting with p85. Cancer Letters 2018, 420:38.
25. Chen H, Zhou L, Wu X, Li R, Wen J, Sha J, Wen X: The PI3K/AKT pathway in the pathogenesis of prostate cancer. Frontiers in Bioscience 2016, 21(5):1084.
26. Slattery ML, Mullany LE, Sakoda LC, Wolff RK, Stevens JR, Samowitz WS, Herrick JS: The PI3K/AKT Signaling Pathway: associations of miRNAs with dysregulated gene expression in colorectal cancer. Molecular Carcinogenesis 2018, 57(2).
27. Zhang Y, Chen P, Yin W, Ji Y, Shen Q, Ni Q: Nectin-4 promotes gastric cancer progression via the PI3K/AKT signaling pathway. Human Pathology 2018, 72:107-116.
28. Ahmad AH, Chan CK, Mohamad J, Abdul HK: Dioscorea bulbifera induced apoptosis through inhibition of ERK 1/2 and activation of JNK signaling pathways in HCT116 human colorectal carcinoma cells. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2018, 104:806.
29. Zhang D, Li X, Yao Z, Wei C, Ning N, Li J: GABAergic signaling facilitates breast cancer metastasis by promoting ERK1/2-dependent phosphorylation. Cancer Letters 2014, 348(1-2):100-108.
30. Zeng H, Jorapur A, Shain AH, Lang UE, Torres R, Zhang Y, Mcneal AS, Botton T, Lin J, Donne M: Bi-allelic Loss of CDKN2A Initiates Melanoma Invasion via BRN2 Activation. Cancer Cell 2018, 34(1):56.
31. Roy S, Laframboise WA, Liu TC, Cao D, Luvison A, Miller C, Lyons MA, O’Sullivan RJ, Zureikat AH, Hogg ME: Loss of Chromatin Remodeling Proteins and/or CDKN2A Associates With Metastasis of Pancreatic Neuroendocrine Tumors and Reduced Patient Survival Times. Gastroenterology 2018.
32. Muthusamy V, Hobbs C, Nogueira C, Cordon-Cardo C, Mckee PH, Chin L, Bosenberg MW: Amplification of CDK4 and MDM2 in malignant melanoma. Genes Chromosomes & Cancer 2010, 45(5):447-454.
33. Orian-Rousseau V: CD44, a therapeutic target for metastasising tumours. European Journal of Cancer 2010, 46(7):1271-1277.
34. Li YS, Jiang BY, Yang JJ, Tu HY, Zhou Q, Guo WB, Yan HH, Wu YL: Leptomeningeal Metastases in Patients with NSCLC with EGFR Mutations. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016, 11(11):1962-1969.
35. Hynes NE, MacDonald G: ErbB receptors and signaling pathways in cancer. Current opinion in cell biology 2009, 21(2):177-184.
36. Cross DA, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, Orme JP, Finlay MR, Ward RA, Mellor MJ et al: AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014, 4(9):1046-1061.
37. Tan CS, Cho BC, Soo RA: Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2016, 93:59-68.
38. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L: AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. New England Journal of Medicine 2015, 372(18):1689.
39. Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R: Rociletinib in EGFR-mutated non-small-cell lung cancer. New England Journal of Medicine 2015, 372(18):1700-1709.
40. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC: Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. Journal of Thoracic Oncology 2015, 10(12):1754-1761.